Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | HBB | P68871 | 2/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | PNP | P00491 | 7/20 | 0.66 |
| ▸ | BLM | P54132 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | EDNRA | P25101 | 1/20 | 0.66 |
| ▸ | HTR2A | P28223 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | POLG | P54098 | 1/20 | 0.61 |
| ▸ | HPRT1 | P00492 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | VCP | P55072 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8445568 | 0.85 | MEN1 (0.73) | MEN1KMT2AHBBMAPK1PNP | |
| SCHEMBL7814355 | 0.85 | MEN1 (0.76) | MEN1KMT2AHBBMAPK1PNP | |
| Valacyclovir SCHEMBL8444387 | 0.85 | MEN1 (1.00) | MEN1KMT2AHBBMAPK1PNP | |
| Valacyclovir SCHEMBL28644 | 0.85 | MEN1 (1.00) | MEN1KMT2AHBBMAPK1PNP | |
| Valacyclovir SCHEMBL4656778 | 0.85 | MEN1 (1.00) | MEN1KMT2AHBBMAPK1PNP | |
| Valacyclovir SCHEMBL13575743 | 0.85 | MEN1 (1.00) | MEN1KMT2AHBBMAPK1PNP | |
| SCHEMBL1177556 | 0.85 | MEN1 (0.66) | MEN1KMT2AHBBMAPK1PNP | |
| Valacyclovir SCHEMBL40830 | 0.84 | HBB (1.00) | MEN1KMT2AHBBMAPK1PNP | |
| Valacyclovir SCHEMBL8320611 | 0.84 | HBB (1.00) | MEN1KMT2AHBBMAPK1PNP | |
| Valacyclovir SCHEMBL5724652 | 0.84 | MEN1 (0.98) | MEN1KMT2AHBBMAPK1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142548-B1 | ACYLATED DERIVATIVE OF THE PURINIC ANTIVIRAL AGENT ACICLOVIR AND USE THEREOF AS A POTENT ANTICANCER AGENT | UNIV RAMOT (IL) | 2016-05-25 | — | — | EP | disclosed |
| US-9334272-B2 | Derivatives of purinic and pyrimidinic antiviral agents and use thereof as potent anticancer agents | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2016-05-10 | — | — | US | disclosed |
| US-9334272-B2 | Derivatives of purinic and pyrimidinic antiviral agents and use thereof as potent anticancer agents | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2016-05-10 | — | — | US | disclosed |
| US-9334272-B2 | Derivatives of purinic and pyrimidinic antiviral agents and use thereof as potent anticancer agents | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2016-05-10 | — | — | US | disclosed |
| US-20140371245-A1 | NOVEL DERIVATIVES OF PURINIC AND PYRIMIDINIC ANTIVIRAL AGENTS AND USE THEREOF AS POTENT ANTICANCER AGENTS | BAR-ILAN UNIVERSITY (IL) | 2014-12-18 | — | — | US | disclosed |
| US-20140371245-A1 | NOVEL DERIVATIVES OF PURINIC AND PYRIMIDINIC ANTIVIRAL AGENTS AND USE THEREOF AS POTENT ANTICANCER AGENTS | BAR-ILAN UNIVERSITY (IL) | 2014-12-18 | — | — | US | disclosed |
| US-20140371245-A1 | NOVEL DERIVATIVES OF PURINIC AND PYRIMIDINIC ANTIVIRAL AGENTS AND USE THEREOF AS POTENT ANTICANCER AGENTS | BAR-ILAN UNIVERSITY (IL) | 2014-12-18 | — | — | US | disclosed |
| US-20110028497-A1 | NOVEL DERIVATIVES OF PURINIC AND PYRIMIDINIC ANTIVIRAL AGENTS AND USE THEREOF AS POTENT ANTICANCER AGENTS | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2011-02-03 | — | — | US | disclosed |
| US-20110028497-A1 | NOVEL DERIVATIVES OF PURINIC AND PYRIMIDINIC ANTIVIRAL AGENTS AND USE THEREOF AS POTENT ANTICANCER AGENTS | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2011-02-03 | — | — | US | disclosed |
| US-20110028497-A1 | NOVEL DERIVATIVES OF PURINIC AND PYRIMIDINIC ANTIVIRAL AGENTS AND USE THEREOF AS POTENT ANTICANCER AGENTS | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2011-02-03 | — | — | US | disclosed |
| EP-2142548-A1 | NOVEL DERIVATIVES OF PURINIC AND PYRIMIDINIC ANTIVIRAL AGENTS AND USE THEREOF AS POTENT ANTICANCER AGENTS | Ramot at Tel-Aviv University Ltd. (IL) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008120205-A1 | NOVEL DERIVATIVES OF PURINIC AND PYRIMIDINIC ANTIVIRAL AGENTS AND USE THEREOF AS POTENT ANTICANCER AGENTS | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371245-A1 | NOVEL DERIVATIVES OF PURINIC AND PYRIMIDINIC ANTIVIRAL AGENTS AND USE THEREOF AS POTENT ANTICANCER AGENTS | NUDT1, NUDT14, TYMP | MEN1 3799/4885KMT2A 2805/4885HBB 4709/4885 |
| US-20110028497-A1 | NOVEL DERIVATIVES OF PURINIC AND PYRIMIDINIC ANTIVIRAL AGENTS AND USE THEREOF AS POTENT ANTICANCER AGENTS | NUDT1, NUDT14, TYMP | MEN1 3799/4885KMT2A 2805/4885HBB 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.